Meridian Bioscience

Meridian Bioscience Payables Turnover

The Payables Turnover Ratio of Meridian Bioscience (VIVO) as of Oct 26, 2026 is 8.15. In the previous year, Payables Turnover Ratio was 9.98 — a change of -18.36% (lower).

Payables Turnover

8.15

YoY

-18.36%

Last updated:

Payables Turnover Ratio of Meridian Bioscience is 2022 8.15 . Payables Turnover Ratio of Meridian Bioscience was 2021 9.98 . It decreases by -18.36% lower compared to the previous year.

The Meridian Bioscience Payables Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Payables Turnover
Date
Payables Turnover
Jan 1, 2015
11.05 USD
Jan 1, 2016
9.07 USD
Jan 1, 2017
9.94 USD
Jan 1, 2018
13.10 USD
Jan 1, 2019
11.43 USD
Jan 1, 2020
8.12 USD
Jan 1, 2021
9.98 USD
Jan 1, 2022
8.15 USD
The Meridian Bioscience Payables Turnover history
YEARPayables TurnoverYoY
8.15-18.36%
9.98+22.93%
8.12-28.99%
11.43-12.71%
13.10+31.81%
9.94+9.59%
9.07-17.92%
11.05-22.87%
14.32—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meridian Bioscience stock

Payables Turnover Ratio of Meridian Bioscience is 8.15 in 2022.

Payables Turnover Ratio of Meridian Bioscience changed from 9.98 to 8.15, representing a -18.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Payables Turnover Ratio Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

Payables turnover measures how quickly a company pays its suppliers. Lower turnover may indicate better payment terms or cash flow management.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Payables Turnover Ratio's Meridian Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate Payables Turnover Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Payables Turnover Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Meridian Bioscience

All Key Metrics — Meridian Bioscience